Migraines

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced it has initiated its Phase 3 clinical program to evaluate MAP0004 as a potential treatment for migraine. MAP0004 is orally inhaled and self-administered at home using MAP Pharmaceuticals’ proprietary Tempo(R) inhaler. In the company’s prior Phase 2 efficacy study, MAP0004 provided pain relief in as fast as 10 minutes, with relief sustained through at least 24 hours.

More: continued here